KR101944914B1 - 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 - Google Patents
치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 Download PDFInfo
- Publication number
- KR101944914B1 KR101944914B1 KR1020147023266A KR20147023266A KR101944914B1 KR 101944914 B1 KR101944914 B1 KR 101944914B1 KR 1020147023266 A KR1020147023266 A KR 1020147023266A KR 20147023266 A KR20147023266 A KR 20147023266A KR 101944914 B1 KR101944914 B1 KR 101944914B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- pyrimidin
- ylamino
- indol
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(IC1)I#I1=C Chemical compound *C(IC1)I#I1=C 0.000 description 1
- KGEDOJBNGRMJLD-VPHISVRJSA-N CC/C=C(\N=C(/C(/C)=C\C)\Cl)/Cl Chemical compound CC/C=C(\N=C(/C(/C)=C\C)\Cl)/Cl KGEDOJBNGRMJLD-VPHISVRJSA-N 0.000 description 1
- OVCACLXDNVIMCX-IRCKDKKWSA-N CC/C=C(\N=C(/C(/C)=C\C)\[n]1nc(C)c(C(OCC)=O)c1)/Cl Chemical compound CC/C=C(\N=C(/C(/C)=C\C)\[n]1nc(C)c(C(OCC)=O)c1)/Cl OVCACLXDNVIMCX-IRCKDKKWSA-N 0.000 description 1
- HHYVTIKYZUMDIL-UHFFFAOYSA-N CCOC(c1c[nH]nc1C)=O Chemical compound CCOC(c1c[nH]nc1C)=O HHYVTIKYZUMDIL-UHFFFAOYSA-N 0.000 description 1
- DIVZNWGPRMIBBX-UHFFFAOYSA-N Cc([n](C)c(cc1)c2cc1Nc1nccc(-[n]3nc(C)c(CN(C4)CC4OC)c3)n1)c2Cl Chemical compound Cc([n](C)c(cc1)c2cc1Nc1nccc(-[n]3nc(C)c(CN(C4)CC4OC)c3)n1)c2Cl DIVZNWGPRMIBBX-UHFFFAOYSA-N 0.000 description 1
- UWQBADOPDPLPHF-UHFFFAOYSA-N Cc(c(CN(C1)CC1O)c1)n[n]1-c1nc(Nc(cc2)cc3c2[n](CCOC)cc3)ncc1 Chemical compound Cc(c(CN(C1)CC1O)c1)n[n]1-c1nc(Nc(cc2)cc3c2[n](CCOC)cc3)ncc1 UWQBADOPDPLPHF-UHFFFAOYSA-N 0.000 description 1
- UCXIKENKSBLXSM-UHFFFAOYSA-N Cc(c(CN(C1)CC1O)c1)n[n]1-c1nc(Nc(cc23)ccc2[n](C)nc3Cl)ncc1 Chemical compound Cc(c(CN(C1)CC1O)c1)n[n]1-c1nc(Nc(cc23)ccc2[n](C)nc3Cl)ncc1 UCXIKENKSBLXSM-UHFFFAOYSA-N 0.000 description 1
- WKFSTNTWRKTPFC-UHFFFAOYSA-N Cc(c(CN(C1)CC1O)c1)n[n]1-c1nc(Nc2ccc3[n](C)cc(C(N4CCCC4)=O)c3c2)ncc1 Chemical compound Cc(c(CN(C1)CC1O)c1)n[n]1-c1nc(Nc2ccc3[n](C)cc(C(N4CCCC4)=O)c3c2)ncc1 WKFSTNTWRKTPFC-UHFFFAOYSA-N 0.000 description 1
- VLSXAYNYBJKZAV-JOCHJYFZSA-N Cc(c(CN(CC1)C[C@@H]1O)c1)n[n]1-c1nc(Nc(cc2)cc3c2[n](C2CC2)cc3C(C2CC2)=O)ncc1 Chemical compound Cc(c(CN(CC1)C[C@@H]1O)c1)n[n]1-c1nc(Nc(cc2)cc3c2[n](C2CC2)cc3C(C2CC2)=O)ncc1 VLSXAYNYBJKZAV-JOCHJYFZSA-N 0.000 description 1
- PHFOPTLWGQJGMW-SZPZYZBQSA-N Cc(c(CN(C[C@H]1O)C[C@@H]1O)c1)n[n]1-c1nc(Nc2ccc3[nH]cc(C(C4CC4)=O)c3c2)ncc1 Chemical compound Cc(c(CN(C[C@H]1O)C[C@@H]1O)c1)n[n]1-c1nc(Nc2ccc3[nH]cc(C(C4CC4)=O)c3c2)ncc1 PHFOPTLWGQJGMW-SZPZYZBQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588793P | 2012-01-20 | 2012-01-20 | |
| US61/588,793 | 2012-01-20 | ||
| PCT/US2013/022135 WO2013109882A1 (en) | 2012-01-20 | 2013-01-18 | Substituted pyrimidine compounds and their use as syk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140135954A KR20140135954A (ko) | 2014-11-27 |
| KR101944914B1 true KR101944914B1 (ko) | 2019-02-07 |
Family
ID=48799685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147023266A Active KR101944914B1 (ko) | 2012-01-20 | 2013-01-18 | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8871778B2 (https=) |
| EP (1) | EP2804861B1 (https=) |
| JP (1) | JP6062962B2 (https=) |
| KR (1) | KR101944914B1 (https=) |
| CN (1) | CN104203943B (https=) |
| AU (1) | AU2013209586B2 (https=) |
| CA (1) | CA2863517C (https=) |
| ES (1) | ES2668479T3 (https=) |
| NZ (1) | NZ627113A (https=) |
| PL (1) | PL2804861T3 (https=) |
| WO (1) | WO2013109882A1 (https=) |
| ZA (1) | ZA201406038B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY184561A (en) * | 2013-10-21 | 2021-04-03 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
| CN103969445B (zh) * | 2014-05-08 | 2015-09-30 | 中南大学 | 亚铁血红素—二氧化锰复合物的制备及其用于检测人IgG的方法 |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| DK3240785T3 (da) | 2014-12-29 | 2021-09-27 | Us Health | Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf |
| ES2906205T3 (es) * | 2017-06-14 | 2022-04-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhibidor de Syk y método de uso para el mismo |
| ES2959967T3 (es) * | 2017-07-28 | 2024-02-29 | Yuhan Corp | Procedimiento de preparación deN-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida |
| AU2020240382B2 (en) | 2019-03-19 | 2022-08-25 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| US20240285621A1 (en) * | 2020-09-23 | 2024-08-29 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060295A1 (en) * | 2009-11-13 | 2011-05-19 | Genosco | Kinase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE240955T1 (de) * | 1996-08-09 | 2003-06-15 | Boehringer Ingelheim Pharma | 4-substituierte beta-carboline als immunomodulatoren |
| US20040235834A1 (en) * | 2003-03-25 | 2004-11-25 | Farmer Luc J. | Thiazoles useful as inhibitors of protein kinases |
| TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| JP5959537B2 (ja) * | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
-
2013
- 2013-01-18 US US13/745,734 patent/US8871778B2/en active Active
- 2013-01-18 NZ NZ627113A patent/NZ627113A/en unknown
- 2013-01-18 ES ES13738382.4T patent/ES2668479T3/es active Active
- 2013-01-18 KR KR1020147023266A patent/KR101944914B1/ko active Active
- 2013-01-18 CA CA2863517A patent/CA2863517C/en active Active
- 2013-01-18 AU AU2013209586A patent/AU2013209586B2/en active Active
- 2013-01-18 JP JP2014553451A patent/JP6062962B2/ja active Active
- 2013-01-18 EP EP13738382.4A patent/EP2804861B1/en active Active
- 2013-01-18 CN CN201380015041.1A patent/CN104203943B/zh active Active
- 2013-01-18 PL PL13738382T patent/PL2804861T3/pl unknown
- 2013-01-18 WO PCT/US2013/022135 patent/WO2013109882A1/en not_active Ceased
-
2014
- 2014-08-18 ZA ZA2014/06038A patent/ZA201406038B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060295A1 (en) * | 2009-11-13 | 2011-05-19 | Genosco | Kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2804861T3 (pl) | 2018-08-31 |
| EP2804861A4 (en) | 2015-07-22 |
| HK1205106A1 (en) | 2015-12-11 |
| US8871778B2 (en) | 2014-10-28 |
| AU2013209586B2 (en) | 2017-08-17 |
| EP2804861B1 (en) | 2018-02-28 |
| KR20140135954A (ko) | 2014-11-27 |
| CN104203943A (zh) | 2014-12-10 |
| NZ627113A (en) | 2016-07-29 |
| CA2863517C (en) | 2019-11-05 |
| US20130274242A1 (en) | 2013-10-17 |
| ZA201406038B (en) | 2015-12-23 |
| WO2013109882A1 (en) | 2013-07-25 |
| ES2668479T3 (es) | 2018-05-18 |
| JP2015504093A (ja) | 2015-02-05 |
| JP6062962B2 (ja) | 2017-01-18 |
| CN104203943B (zh) | 2017-12-29 |
| EP2804861A1 (en) | 2014-11-26 |
| AU2013209586A1 (en) | 2014-07-24 |
| CA2863517A1 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101944914B1 (ko) | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 | |
| JP6359020B2 (ja) | Ａｌｋキナーゼ阻害剤 | |
| CN102459187A (zh) | Janus激酶抑制化合物和方法 | |
| KR20140144709A (ko) | 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도 | |
| KR102228034B1 (ko) | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 | |
| CA3161339A1 (en) | Cyclic compounds and methods of using same | |
| KR20090092317A (ko) | 키나제 억제제로서의 화합물 및 조성물 | |
| JP6483656B2 (ja) | キナーゼ活性のモジュレータとしての６−［４−（１ｈ−イミダゾール−２−イル）ピペリジン−１−イル］ピリミジン−４−アミン誘導体 | |
| CN101489559A (zh) | 作为药物化合物的嘌呤和脱氮嘌呤衍生物 | |
| HK1205106B (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| AU2024284667A1 (en) | Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase | |
| HK1226395B (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| BR112016008060B1 (pt) | Composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| P14-X000 | Amendment of ip right document requested |
St.27 status event code: A-5-5-P10-P14-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 8 |